OncoMatch/Clinical Trials/NCT05521802
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Is NCT05521802 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell for multiple myeloma.
Treatment: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell — This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
including at least one proteasome inhibitor
Must have received: immunomodulatory drug
including at least one ... immunomodulatory drug
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation (HSCT) at anytime
Cannot have received: autologous stem-cell transplantation
Exception: within 12 weeks prior to apheresis
autologous stem-cell transplantation (ASCT) within 12 weeks prior to apheresis
Cannot have received: CAR-T cell therapy
Previous CAR-T cell treatment
Cannot have received: genetically modified T-cell therapy
genetically modified T-cell therapies
Cannot have received: BCMA-directed treatment
BCMA-directed treatment history
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify